Keywords
Vitamin D, Uterine fibroid, Hypovitaminosis, Small burden, Leiomyoma
Research Article
S. Al-azzawi et al. Pharm Sci Asia 2022; 49(4), 333-339
334
management, and in the first place among these strategies
is the prevention of its occurrence. It is known that
vitamin D3 acts as a regulator of calcium homeostasis
in addition to its strong antifibrotic activity14. Moreover,
studies have reported vitamin D3 as a potent antitumor
factor that efficiently inhibits uterine fibroid in cell culture
and shrinks fibroid in animal studies. However, there are
not enough clinical trials conducted in the human uterine
regarding this area of research1,12,15-16.
Vitamin D deficiency is associated with enormous
unfavorable conditions, in particular, osteomalacia and
rickets17. Low levels of vitamin D have previously been
detected in women with osteoporosis and metabolic
syndrome, which in turn emphasizes the value of vitamin
D in women’s general health18-19.
Vitamin D can be found within the diet, such as cod
liver oil, oily fish and dairy products. However, the main
vitamin D source is sun exposure, where ultra-violet light
transforms 7-dehydrocholesterol in the skin to vitamin
D via a nonenzymatic isomerization. After that, vitamin
D is subjected to metabolic biotransformation in the liver
by 25α-hydroxylase to 25 -hydroxyvitamin-D; which is
then converted in the kidney to the active form (1,25 -
dihydroxyvitamin-D) (vitamin D3) by the action of 1α-
hydroxylase20. Vitamin D3 exerts its biological activities
in cells by interacting with its specific receptor, vitamin
D receptor (VDR). VDR is “a nuclear transcription
factor”, it plays an important role in gene expression
modulation and trans cription. VDR affects the cell
signalling such as “growth arrest, differentiation and/or
induction of apoptosis”, which in turn inhibits cell
growth1,21.
It has been recently suggested that vitamin D defi-
ciency is associated with increasing uterine fibroids risk
1-2,4,22. Vitamin D acts as a potent antiprogesteronic and
antiestrogenic compound and can inhibit leiomyoma cell
proliferation. Furthermore, vitamin D was found to inhibit
the growth of fibroid cells and also promotes cell apoptosis
in in vitro culture, whereas in in vivo animal models, it
reduced the fibroid size.
Several previous epidemiological studies conducted
in different populations emphasized the importance of
vitamin D deficiency in the development of UFs 24-26.
Nevertheless, no study so far has ever addressed this
issue in the Iraqi population (country in the Middle East)
especially in Hilla city (located in the middle area of Iraq)
where it is considered a hot region with high levels of
sunlight exposure. Therefore, this study aims to investi-
gate the relationship of occurrence of fibroids in women
diagnosed with uterine fibroid with vitamin D deficiency
in Hilla city.
2. SUBJECTS AND METHODS
The cross -section study was conducted in 2021
during the summer season, from June to October, to ex-
clude deficiency of vitamin D associated with the winter
season, on a sample of 70 subjects. The participants were
recruited among the female patients attended private
gynecological clinics and were referred to biochemical
analytical laboratories in Hilla city.
A female subject was considered eligible to partici-
pate in the study if she presented with uterine fibroid that
was detected by ultrasound scan (transvaginal or abdo -
minal) and all types of fibroids (subserosal, submucosal,
intramural and pedunculated fibroids) as appeared in the
reports were included. Information from their ultrasound
scan reports were considered as variables in the study
including the size of fibroids; small (3 cm) 27 and number of fibroids
(single or multiple).
The medical history and clinical features for each
patient were recorded as a questionnaire to include the
following parameters: age, “body mass index (BMI)”,
previous or current intake of vitamin D supplements or
not and a history of disease. Fibroids-related symptoms
such as menstrual disorders and pelvic pain (which are
classified as minor, mild or severe) were also reported.
Women with a history of intake of vitamin D supple -
ments and those who followed a special diet regimen due
to weight lowering or disease were excluded from the
study. In addition, women with chronic disease (such as
cardiovascular and central nervous system disorders,
diabetes mellitus, autoimmune diseases) were also
excluded.
Vitamin D3 lev els were obtained from laboratory
biochemical analysis reports which were measured in
the serum of participants using MINI VIDAS system
(France)28 to study the effect of vitamin D3 levels on the
incidence of UF. Vitamin D deficiency was deemed
when serum levels were 30 ng/mL29. Data of the patients
with vitamin D3 deficiency and insufficiency were
analyzed to evaluate the relationship between vitamin D
and the tested variables (age, BMI, severity of symptoms
and the size and number of fibroids). To study the
relationship of vitamin D concentration with age factor,
participants were stratified into four groups (45 years) whereas for BMI factor, they were
grouped into four groups (40).
2.1. Statistical analysis
The data in this work were collected and expressed
as percentages or means±standard deviation (represented
by error bars) using Excel Microsoft. The data were
analyzed by ANOVA an d Tukeys test using Minitab
software, and probability <0.05 is considered for the
significant differences.
Pharmaceutical Sciences Asia
335
3. RESULTS AND DISCUSSION
In this study, 70 women diagnosed with fibroids
were recruited and their vitamin D3 serum levels were
evaluated. The results revealed that 56% of the parti ci-
pants were with deficient vitamin D3 values (30 ng/
mL) (Figure 1).
Figure 1. Percentages of women having normal, insufficient and
deficient vitamin D levels associated with uterine fibroids.
To evaluate the association of vitamin D deficiency
with the age factor, women were stratified into four age
groups. It is of note that the youngest women (45 showed significant dif-
ferences (p<0.05) in vitamin D levels from the <35 group.
Significant differences (p<0.05) were found in compari-
son with the group of control women matched per age
(Figure 2).
Figure 2. Vitamin D levels within age subgroups for women with
uterine fibroids with comparison to control groups. Significant diffe-
rences (p40 subgroups and
<40 subgroups(+).
This is consistent with the previous findings that
have documented a positive correlation between age and
serum vitamin D concentrations31-32. It has been reported
that low vitamin D levels associated with increasing age
is due to several factors including reduction in calcium
absorption with increasing “intestinal resistance” to
vitamin D31, low expression of VDR5, and reduced renal
production of vitamin D by the kidneys 31. Obesity and
lack of outdoor activity by the older women may also
contribute to the vitamin D deficiency33. Therefore, con-
sumption of vitamin D-rich food with increasing sunlight
exposure are required for people aged more than 41 years
to avoid vitamin D deficiency.
The data regarding BMI showing the lowest vita -
min D3 levels were noticed with high BMI (>30) group,
whereas the highest levels of the vitamin (19.1±5 ng/mL)
were observed with low BMI (0.05) within the tested
subgroups (Figure 3).
Figure 3. Vitamin D levels within BMI subgroups for women with
uterine fibroids.
Considering other studies, it has been shown that
obesity is “independently correlated” with vitamin D
deficiency34. A previous study has demonstrated that
vitamin D deficiency was found in more than 50% of
obese individuals (BMI ≥40)35. The relationship between
obesity and vitamin D is not clear and still unknown,
and may be explained by the presence of “excess body
fat tissue” that retain vitamin D resulting in an increase
in the volume of distribution of the vitamin, which in
turn causes a decrease in the circulatory vitamin D levels.
Alternatively, metabolic syndromes could also be the
reason behind the vitamin D deficiency as overweight is
considered as one of its main components34. It has been
found that vitamin D deficiency is associated with meta-
bolic syndrome especially in postmenopausal women18.
Further explanation may link obesity with vitamin D
deficiency is that obese individuals have higher cortical
tissue mineral density and cortical thickness than thin
ones have or may due to differences between obese and
normal subjects in liver enzymes expression that activate
vitamin D33.
The severity of symptoms associated with UF was
S. Al-azzawi et al. Pharm Sci Asia 2022; 49(4), 333-339
336
also evaluated to detect any suspected effects of vitamin
D deficiency. In this regard, women with mild to mode-
rate symptoms were associated with the lowest values
of vitamin D (16.3±2 ng/mL) while highest values (20.2±
4 ng/mL) were detected in individuals with minor symp-
toms (Figure 4). However, there were no significant
differences (p>0.05) within groups of severity of symp-
toms (minor, mild or severe). These controversial results
could be attributed to the inaccurate information given
by some patients or some of them have tolerated these
symptoms or underestimated them (pain-threshold varia-
tions from patient to patient).
Figure 4. Vitamin D levels according to severity of symptoms asso-
ciated with uterine fibroids.
To identify any potential correlation between vita-
min D deficiency and the incidence of UF, serum levels
were investigated according to the size and number of
fibroids in the involved subjects. As expected, th e con-
centrations of vitamin D were found to be significantly
(p<0.05) lower in patients with large size fibroids (14.8
±2 ng/mL) than in those have small ones (20.9±3 ng/mL)
(Figure 5). Interestingly, the serum levels of vitamin D
were found at its lowest concentrations (12.9±4 ng/mL)
in the cases with multiple number of fibroids with signi-
ficant differences (p<0.05) when compared to that of the
single fibroid cases (22.6±3 ng/mL) (Figure 5).
Figure 5. Vitamin D levels according to size and number of fibroids.
Significant differences (P<0.05) were found between small and large
size subgroups and between single and multiple fibroids subgroups
(+).
Thence, current findings demonstrated the crucial
role of vitamin D deficiency in developing fibroids and
increasing cell growth and proliferation. As previously
reported, vitamin D has potent anti -tumor activity by
inhibiting “leiomyoma cell proliferation”4,24, this is also
supported by other studies that have proposed its
potential role in the non-surgical management of uterine
leiomyoma9,14,16. It has been previously postulated that
vitamin D could exert an antiproliferative action on
uterine cells through arresting cell growth and inhibition
of “Wnt/β -catenin pathway”, suggesting its effective
option in stabilizing leiomyoma size and preven ting its
growth36. It has been demonstrated that increasing
vitamin D concentration was correlated with inhibition
of UF cell growth 15,23. Further study has shown the
inhibitory effect of vitamin D3 on the “transforming
growth factor beta” (TGF-β) pathway that is deemed to
be the main fac tor in the developing of “fibrosis -asso-
ciated diseases” confirming the role of this vitamin in
the fibroid pathogenesis. Furthermore, vitamin D may
act as a potent antiprogesteronic and antiestrogenic
compound, and upon vitamin D supplementation, the
progesteronic and estrogenic receptors expression
decreased and the VDR up-regulation increased resulting
in reducing disease progression 9. In addition, it is
believed that “human uterine leiomyoma” contains lower
vitamin D3 concentrations than its adjacent myome -
trium30. Another study has suggested that vitamin D3
reduces UF growth via modulating the up -regulation
and activities of “matrix metalloproteinase-2 and -9 and
it is considered a promising natural substance with anti-
uterine fibroid properties3. Other several in vivo and in
vitro studies have shown the effectiveness of vitamin D
in reducing the size and the frequency of leiomyomas
25,37. Recent studies have demonstrated that a combined
supplementation of vitamin D plus epigallocatechin
gallate could reduce myomas’ volume and improve
women’s quality of life38.
As a result, vitamin D3 supplementation seems to
be beneficial to ameliorate the difficulties associated
with, or even preventing, UFs, which in turn may
improve women’s health. Vitamin D can regulate cells
proliferation and differentiation, inhibit angiogenesis,
and stimulate cells apoptosis, consequently, this leads to
inhibition of tumorous tissue growth and of neoplastic
formation associated with fibroids of the uterus 9,36.
Another explanation for the role of vitamin D supple -
ments on reduction of fibroids progression by recove-
ring the damaged DNA, including suppression of the
UF's phenotype via orchestrated addressing at multiple
molecules of the DNA repa iring pathways 39. Vitamin
D3 is found able to shrink the UF growth and reverse
several abnormal biological pathways by ameliorating
Pharmaceutical Sciences Asia
337
the developmental exposure -induced DNA damages
and inflammatory pathways in primed myometrial stem
cells40.
Vitamin D deficiency has become a common
dilemma associated with many health problems and its
consequences could not be underestimated. Chronic
conditions are usually multifactorial, yet they could
easily be overcome; however, vitamin D is considered
an effective and potent, safe and low-cost treatment that
can also be taken as a prophylactic agent 14,23. Although
sun exposure is the “ideal source” of vitamin D, most
individuals, in reality, have hypovitaminosis D and need
supplementation. Vitamin D deficiency was found pan-
demic even in “sun-drenched” countries and associated
with tremendous negative health consequences. The
skin is capable of production of vitamin D supplying 80-
100% of the body’s requirements of vitamin D. However,
age, time of day, latitude, season and pigmentation can
influence the production of vitamin D in the skin 41.
Generally, people avoid the sun because of the overex -
posure dangers. Moreover, many of “life’s obligations”
force us to spend most of our time inside under fluores-
cent lights, keeping us away from natural sunlight. In
addition, the cultural differences in clothing and Muslim
dress style could have impact on sunlight exp osure, as
many Iraqi women cover their bodies with hejab or
abaya that limits the skin’s exposure to sunlight and
lowers the ability to synthesize vitamin D 42. Therefore,
health in ge neral and vitamin D levels, in particular,
must be checked routinely to unearth any latent disease
or even to prevent its manifestation via modifying the
risk factors. In Iraq, the temperature in summer may
reach over 50○C that prevents most people from getting
outside or doing any outdoor activities. Hence, vitamin
D supplementation might be considered especially for
people at high risk factors and for women at their
reproductive age to avoid occurrence or progression of
fibroids.
To reach sufficient serum vitamin D3 concentration
(75 nmol/L), according to previous studies, different daily
vitamin D supplemental intakes were recommended
depending on region, status and age of individuals. For
instance, the dose of 2250 IU/day for pregnant women
and of 2026 IU/day for adults in Middle East area is
suggested37,43. Adverse effects associated with vitamin D
self-administration such as hypercalciuria and hypercal-
cemia are rare, and usually due to taking it for a long time
with extremely high doses44. In addition, many nutrients
and dietary habits can be associated with myoma develop-
ment risk, so dietary supplements should be considered
for women with UF such as food rich with fibres, and
fish oil as well some fruits and vegetables, especially the
coloured ones, these can help in improving health and
potentiating the action of vitamin D i n preventing the
progression of diseases45-46.
4. CONCLUSION
Vitamin D3 plays a potential role in UF pathoge -
nesis and its severity. In spite of the fact that the region
where the study was conducted is considered sunny,
people may suffer from vitamin D deficiency due to life-
style and low sun exposure. Natural vitamin D sources
and supplements seem to be promising, b eneficial, and
inexpensive tools in the fight against UFs and in allevia-
ting their progression. A recent study has found the
administration of vitamin D supplements could reduce
the recurrence rates of UFs and the size of recurrent UFs
47. Vitamin D with specific anti UF drugs could provide
a synergistic effect and is an interesting issue to be further
studied.
5. ACKNOWLEDGEMENT
Authors would like to thank private clinics and cli-
nical biochemistry laboratories staff in Hilla, in particular
Ahmed Al -khafaji and Zaid Jawdet for their helpful
participation during collection and analysis of samples
of this study.
Author contributions
SA designed the whole study, collected the data and
wrote the manuscript. DM and RK collected the data,
analyzed the study data and edited the manuscript.
Conflict of interest
None to declare.
Funding
None to declare.
List of abbreviations
BMI= Body Mass Index
ECM= Extracellular matrix
TNF-α= Tumor necrosis factor α
UF= Uterine fibroid
VDR= Vitamin D receptor
Ethics approval and consent to participate
All patients in this study were asked for their consent to
participate and the study protocol was approved by the
local ethics committee. Permission was authorized by the
Committee of Research Ethical Approval, COP, Uni -
versity of Babylon, Iraq, on 20/April/2021 (Reference
no.: COPSEC 2021-O3).
Article info:
Received February 2, 2022
Received in revised form April 11, 2022
Accepted May 17, 2022
S. Al-azzawi et al. Pharm Sci Asia 2022; 49(4), 333-339
338
References
1. Al-Hendy A, Badr M . Can vitamin D reduce the risk of uterine
fibroids?. Womens Health (Lond Engl). 2014;10(4):353-8.
2. Ciebiera M, Włodarczyk M, Ciebiera M, Zaręba K, Łukaszuk K,
Jakiel G. Vitamin D and Uterine Fibroids-Review of the Litera-
ture and Novel Concepts. Int J Mol Sci. 2018;19(7):2051.
3. Halder SK, Osteen KG, Al-Hendy A. Vitamin D3 inhibits expres-
sion and activities of matrix metalloproteinase-2 and -9 in human
uterine fibroid cells. Hum Reprod. 2013;28(9):2407-16.
4. Brakta S, Diamond JS, Al-Hendy A, Diamond MP , Halder SK.
Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015;
104(3):698-706.
5. de Jongh RT, van Schoor NM, Lips P . Changes in vitamin D
endocrinology during aging in adults. Mol Cell Endocrinol.
2017;453:144-50.
6. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar
S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Pri -
mers. 2016;2(1):16043.
7. McWilliams MM, Chennathukuzhi VM. Recent Advances in
Uterine Fibroid Etiology. Semin Reprod Med. 2017;35(2):181-9.
8. Tinelli A, Catherino WH, Gargiulo AR, Hurst BS, Mynbaev OA,
Vergara D, et al. Uterine Fibroids: From Molecular Oncology to
Reproduction. Biomed Res Int. 2018;2018:6284875.
9. Ciavattini A, Delli Carpini G, Serri M, Vignini A, Sabbatinelli J,
Tozzi A, et al. Hypovitamino sis D and "small burden" uterine
fibroids: Opportunity for a vitamin D supplementation. Medicine
(Baltimore). 2016;95(52):e5698.
10. Navarro A, Bariani MV, Yang Q, Al-Hendy A. Understanding the
Impact of Uterine Fibroids on Human Endometrium Function.
Front Cell Dev Biol. 2021;9:633180.
11. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ,
Segars JH. The estimated annual cost of uterine leiomyomata in
the United States. Am J Obstet Gynecol. 2012;206(3):211.e1-9.
12. Angioni S, D'Alterio MN, Daniilidis A. Highlights on Medical
Treatment of Uterine Fibroids. Curr Pharm Des. 2021;27(36):
3821-32.
13. Dinis-Oliveira RJ. Pharmacokinetics, toxicological and clinical
aspects of ulipristal acetate: insights into the mechanisms impli-
cated in the hepatic toxicity. Drug Metab Rev. 2021;53(3):375-83.
14. Ali M, Al -Hendy A, Yang Q. Vitamin D, a promising natural
compound with anti-uterine fibroid characteristics. Fertil Steril.
2018;111(2):268-9.
15. Vergara D, Catherino WH, Trojano G, Tinelli A. Vitamin D:
Mechanism of Action and Biological Effects in Uterine Fibroids.
Nutrients. 2021;13(2):597.
16. Donnez J, Donnez O, Dolmans MM. The current place of medi-
cal therapy in uterine fibroid management. Best Pract Res Clin
Obstet Gynaecol. 2018;46:57-65.
17. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):
266-81.
18. Schmitt EB, Nahas-Neto J, Bueloni-Dias F, Poloni PF, Orsatti CL,
Petri Nahas EA. Vitamin D deficiency is associated with meta -
bolic syndrome in postmenopausal women. Maturitas. 2018;
107:97-102.
19. Fichera M, Török P, Tesarik J, Della Corte L, Rizzo G, Garzon S,
et al., Vitamin D, reproductive disorders and assisted reproduc -
tion: evidences and perspectives. Int J Food Sci Nutr. 2020;71
(3):276-85.
20. Bikle D. Nonclassic actions of v itamin D. J Clin Endocrinol
Metab. 2009;94(1):26-34.
21. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol
Metab. 2010;95(2):471-8.
22. Singh V, Barik A, Imam N. Vitamin D3 Level in Women with
Uterine Fibroid: An Observational Study in Eastern In dian
Population. J Obstet Gynaecol India. 2018;69:161-5.
23. Bläuer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D
inhibits myometrial and leiomyoma cell proliferation in vitro .
Fertil Steril. 2009;91(5):1919-25.
24. Ciebiera M, Ali M, Prince L, Zgliczyński S, Jakiel G, Al-Hendy
A. The Significance of Measuring Vitamin D Serum Levels in
Women with Uterine Fibroids. Reprod Sci. 2020;28(2):2098-109.
25. Sabry M, Halder SK, Allah AS, Roshdy E, Rajaratnam V, Al -
Hendy A. Serum vitamin D3 level inversely correlates with ute-
rine fibroid volume in different ethnic groups: a cross -sectional
observational study. Int J Womens Health. 2013;5:93-100.
26. Xu F, Li F, Li L, Lin D, Hu H, Shi Q. Vitamin D as a risk factor
for the prese nce of asymptomatic uterine fibroids in premeno -
pausal Han Chinese women. Fertil Steril. 2021;115(5):1288-93.
27. Moshesh M, Peddada SD, Cooper T, Baird D. Intraobserver
variability in fibroid size measurements: estimated effects on
assessing fibroid growth. J Ultrasound Med. 2014;33(7):1217-24.
28. Moreau E, Bächer S, Mery S, Le Goff C, Piga N, Vogeser M, et
al., Performance characteristics of the VIDAS® 25-OH Vitamin D
Total assay-comparison with four immunoassays and two liquid
chromatography-tandem mass spectrometry methods in a
multicentric study. Clin Chem Lab Med. 2016;54(1):45-53.
29. Holick MF, Binkley NC, Bischoff -Ferrari HA, Gordon CM,
Hanley DA, Heaney RP, et al., Evaluation, Treatment, and Pre -
vention of Vitamin D Deficiency: an Endocrine Society Clinical
Practice Guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30.
30. Othman ER, Ahmed E, Sayed AA, Hussein M, Abdelaal II, Fetih
AN, et al., Human uterine leiomyoma contains low levels of 1,
25 dihdroxyvitamin D3, and shows dysregulated expressi on of
vitamin D metabolizing enzymes. Eur J Obstet Gynecol Reprod
Biol. 2018;229:117-22.
31. Gallagher JC. Vitamin D and aging. Endocrinol Metab Clin North
Am. 2013;42(2):319-32.
32. Nasri H, Ardalan MR. Association of serum vitamin D level with
age in individuals with normal renal function. J Nephropharmacol.
2012;1(1):7-9.
33. Vranić L, Mikolašević I, Milić S. Vitamin D Deficiency: Conse-
quence or Cause of Obesity?. Medicina (Kaunas). 2019;55(9):541.
34. Forrest KY, Stuhldreher WL. Prevalence and correlates of
vitamin D deficiency in US adults. Nutr Res. 2011;31(1):48-54.
35. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA,
Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is asso-
ciated with the metabolic syndrome in morbid obesity. Clin Nutr.
2007;26(5):573-80.
36. Corachán A, Ferrero H, Aguilar A, Garcia N, Monleon J, Faus A,
et al., Inhibition of tumor cell proliferation in human uterine leio-
myomas by vitamin D via Wnt/β -catenin pathway. Fertil Steril.
2018;111(2):397-407.
37. Arjeh S, Darsareh F, Asl ZA, Azizi Kutenaei M. Effect of oral
consumption of vitamin D on uterine fibroids: A randomized
clinical trial. Complement Ther Clin Pract. 2020;39:101159.
38. Miriello D, Galanti F, Cignini P, Antonaci D, Schiavi MC, Rago
R. Uterine fibroids treatment: do we have new valid alternative?
Experiencing the combination of vitamin D plus epigallocatechin
gallate in childbearing age affected women. Eur Rev Med Phar-
macol Sci. 2021;25(7):2843-51.
39. Ali M, Shahin SM, Sabri NA, Al -Hendy A, Yang Q. Hypovita-
minosis D exacerbates the DNA damage load in human uterine
fibroids, which is ameliorated by vitamin D3 treatment. Acta
Pharmacol Sin. 2019;40(7):957-70.
40. Elkafas H, Badary O, Elmorsy E, Kamel R, Yang Q, Al-Hendy A.
Endocrine-Disrupting Chemicals and Vitamin D Deficiency in
the Pathogenesis of Uterine Fibroids. J Adv Pharm Res. 2021;5
(2):260-75.
41. Harinarayan CV, Akhila H. Modern India and the Tale of Twin
Nutrient Deficiency -Calcium and Vitamin D -Nutrition Trend
Data 50 Years-Retrospect, Introspect, and Prospect. Front Endo-
crinol (Lausanne). 2019;10:493.
42. Al-Yatama FI, AlOtaibi F, Al-Bader MD, Al-Shoumer KA. The
Effect of Clothing on Vitamin D Status, Bone Turnover Markers,
and Bone Mineral Density in Young Kuwaiti Females. In t J
Endocrinol. 2019;2019:6794837.
43. Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. Regional
Pharmaceutical Sciences Asia
339
variation and determinants of vitamin D status in sunshine-abun-
dant Thailand. BMC Public Health. 2011;11(1):853.
44. Pludowski P, Holick MF, Grant WB, Konstantynowicz J, Mas-
carenhas MR, Haq A, et al., Vitamin D supplementation guide -
lines. J Steroid Biochem Mol Biol. 2018;175:125-35.
45. Masheta DQ, Al -Azzawi SK. Antioxidant and Anti -Inflamma-
tory Effects of Delphinidin on Glial Cells and Lack of Effect on
Secretase Enzyme. IOP Conf Ser: Mater Sci Eng. 2018;454(1):
012061.
46. Tinelli A, Vinciguerra M, Malvasi A, Andjić M, Babović I,
Sparić R. Uterine Fibroids and Diet. Int J Environ Res Public
Health. 2021;18(3):1066.
47. Vahdat M, Allahqoli L, Mirzaei H, Giovannucci E, Salehiniya
H, Mansouri G, et al. The effect of vitamin D on recurrence of
uterine fibroids: A randomized, double-blind, placebo-controlled
pilot study. Complement Ther Clin Pract. 2022;46:101536.